Podcasts about lnp

If you are worried about China taking over due to having better robots than the yanks, I got mixed messages for ya here. This was created using DeepSeek v4 Pro. Remember when DeepSeek could do the same thing as chatGPT but on shitty processors and not much RAM? All those stocks shit themselves? Oh what memories. Would have been a great time to buy NVIDIA stocks. I didn't, if you're asking....It's pretty good but it really didn't follow the instruction in the prompt that Joel Hill is Jack the Insider on the transcript. So that's a minus point. But also, this took fucking ages to generate. It's better than lots of the yankee slop but damn son this took MINUTES. So they might take over if we are patient or whatever. Enjoy the episode. ----------------------------------------------Joel Hill (Jack the Insider) and Hong Kong Jack return for a sprawling episode that tackles two of the biggest stories shaping politics in 2026. The pair open with the jaw-dropping Redbridge poll putting One Nation at 31% of the primary vote — a number that would all but wipe the National Party off the federal map and potentially deliver Anthony Albanese a strengthened majority government by splintering the right. Joel and Jack clash over whether culture-war grievances or material concerns are driving the surge, while drawing historical parallels to Joh for Canberra and the DLP split of the 1950s.The conversation then crosses hemispheres for a tour through UK chaos: Peter Mandelson's leaked dossier exposing a rudderless No. 10 under Keir Starmer, Nicola Sturgeon's estranged husband pleading guilty to embezzling SNP donations on a surreal shopping spree of Lalique salt shakers, seven Dysons, and a motorhome with four miles on the clock, and a deeply troubling police body-cam incident that has reignited the two-tier policing debate ahead of three critical by-elections.The centrepiece of the episode is a sober, hour-long deep dive into the COVID-19 pandemic and what Australia has refused to learn. The Two Jacks lay out the true death toll (perhaps 22 to 69 million globally), the devastating scale of long COVID, the vaccine rollout failures, the absurdities of hotel quarantine with rubbish bags over heads, and why governments and public health officials are desperate to avoid a Royal Commission. They close by asking whether the next pandemic will meet a population that has permanently lost trust in its leaders — and whether we'll simply repeat the mistakes of both COVID and the Spanish flu.Sport provides a lighter coda: the Carlton revival under an interim coach, James Hird's awkward candidacy at Essendon, the expanded 48-team World Cup that nobody seems excited about, and a formidable New Zealand Test side taking on England at Lord's.00:00:25 — Introduction Joel welcomes listeners to Episode 159, recorded 4 June. Today: Australian political news, a check-in on the UK, and a deep dive into the COVID-19 pandemic.00:01:21 — The Redbridge Poll: One Nation at 31% The AFR's Redbridge poll: One Nation 31%, Labor 28%, LNP 20%, Greens 12%. The two-party preferred is now being calculated as One Nation versus Labor — a seismic shift in how Australian politics is measured.00:03:12 — Not Just a Protest Vote Jack argues this is real, not a re-run of Hanson's 1990s flash-in-the-pan. The South Australian state election and the Farrah by-election suggest One Nation support is durable. Joel counters that protest votes can be expressed at the ballot box and that Australians are tiring of pluralism.00:04:09 — If One Nation Succeeds, Labor Wins The cruel irony: One Nation's rise probably delivers Labor government. The National Party could simply disappear. The DLP kept the Coalition in power for decades as an anti-Labor party; One Nation may do the reverse.00:05:46 — Scrutiny and Splintering Joel notes One Nation's policies are "two-sentence fragments" and motherhood statements. When proper scrutiny arrives, the contradictions will surface. Hanson's parliamentary attendance is as poor as imaginable.00:08:22 — The Third Rail Jack argues populists succeed because they discuss what polite society won't: immigration, culture wars, welcome to country rituals. The major parties must engage these topics or cede the ground entirely.00:11:34 — Feeling Unheard The core driver, Jack contends: voters feel sneered at and silenced by mainstream politics. It's not about flag counts, it's about being listened to.00:13:50 — What Actually Drives Votes Joel pushes back: voting determinants are the household economy, migration, climate change — not culture war trivia. Culture wars "don't amount to a hill of beans" at the ballot box.00:14:51 — The DLP Parallel Both agree the One Nation phenomenon most closely resembles the DLP split of the 1950s and 60s — a right-wing fracture that delivered Labor government after Labor government.00:17:18 — The Republic Referendum Lesson Jack recalls the 1999 republic referendum: pro-republicans split between models rather than uniting, scuppering the whole project. Voters will vote their preference even knowing it helps their enemy.00:19:32 — UK Parallels: Accommodate or Fight? Significant figures in the UK Tory party are debating whether to fight Reform or reach an accommodation. Tony Abbott recently said the Liberal Party won't criticise Pauline Hanson.00:21:48 — Joh for Canberra Redux Imre Salusinszky's comparison: this is "Joh for Canberra" all over again. But Joel notes Joh's moment lasted months; One Nation's has already lasted years.00:24:08 — State Election Previews Joel predicts the Victorian state election will be chaotic and peculiar — a government that's been in power too long, an opposition that may not be up to the task, and One Nation peeling votes from safe Labor seats. NSW will give a clearer reading.00:25:44 — Hanson "Ready to Govern" — from the Senate? Pauline Hanson announced she's ready to govern. Joel asks: shouldn't she contest a lower-house seat first? Jack recalls the only precedent: John Gorton became PM while still a senator, but had to be eased into Kooyong.00:28:20 — The Mandelson Dossier: Starmer's Empty Suit Jack's read of the leaked Mandelson documents: ministers don't know what the PM wants, there's zero respect or fear of his authority. Starmer comes across as an empty chair. One minister's text: "Every meeting with Labour MPs — it's all about who can we tax to pay benefits to other people."00:30:50 — Mandelson's Legal Peril Mandelson is under police investigation for misconduct in public office. Could face charges — the seriousness depends on whether it's mere misconduct or genuine bribery for foreign interests.00:31:49 — The Nicola Sturgeon Saga Her estranged husband has pleaded guilty to embezzling roughly £400,000 in SNP donations. The shopping list: six high-end coffee machines, seven Dyson vacuums, Lalique salt and pepper shakers, Montblanc pens, Swiss watches, an iJag, part of a Volkswagen, and a motorhome with four miles on the clock parked at his 92-year-old mother's house. Nicola claims she "didn't go in the kitchen much."00:34:20 — The BBC Interview Laura Kuenssberg's forensic interview with Sturgeon — "not quite Prince Andrew, but not much better." Sturgeon has been cleared by Police Scotland, but her reputation, already damaged by the Alex Salmond trial, is now in tatters.00:35:05 — Will He Go to Prison? £400,000 is a substantial sum. With another £600,000 unaccounted for, a custodial sentence seems likely. The money was ring-fenced for a second independence referendum push.00:36:50 — Money Laundering or Conspicuous Consumption? Joel wonders if the bizarre purchases — multiple watches on the same day — were an amateur money-laundering attempt: buy goods with SNP funds, sell them quietly for cash.00:38:23 — UK By-elections: Makerfield Looms Three by-elections on 18 June, including the critical Makerfield contest. Andy Burnham, Greater Manchester's high-profile mayor, is the tepid favourite. Low turnout could help him return to Westminster.00:39:30 — The Body-Cam Incident A white teenager accused of racially vilifying a Sikh man was stabbed — and police arrested the bleeding victim, not the attacker. Body-cam footage shows the victim saying "I can't breathe, I've been stabbed" while officers dismiss him. Joel calls the footage "just awful."00:41:22 — Two-Tier Policing Jack traces UK policing's overcorrection: after the Macpherson/Lawrence report, guidelines were rewritten so aggressively that they've produced a pattern of questionable enforcement that devastates community trust — and plays directly into Tommy Robinson's hands.00:42:08 — NSW Police on Four Corners Joel recommends the harrowing Four Corners investigation: bashings in custody, false arrests, an officer who threw body-cam footage into Sydney Harbour, and two undercover officers jailed for a savage assault. The problem today is general duties policing, not the specialist squads of the 1980s. Some command areas are far worse than others — a leadership failure.00:44:55 — Victoria Police: Under-Resourced, Not Corrupt Joel shares an anecdote: two divisional vans for 80,000 people in outer-east Melbourne. Tough work being a police officer; even tougher being a good one.The COVID-19 Reckoning00:45:09 — Why This Matters Joel sets the frame: we parked COVID in 2023 with a hangover but never understood what we'd been through. Today's episode aims to crack that problem.00:45:51 — The True Death Toll Officially: 7 million dead. But most countries stopped testing and stopped reporting cause-of-death data to the WHO. Using excess mortality, the real toll is between 22 and 69 million — at the high end, exceeding the Spanish flu.00:47:02 — Long COVID's Shadow Roughly 400 million people globally (6% of the population) have experienced long COVID. In Australia alone, between 200,000 and 500,000 people are living with or have lived with the condition. Second infections can be worse. Emerging links to cardiovascular disease, type 2 diabetes, and accelerated dementia.00:49:43 — The Collective Amnesia Governments worldwide have "a collective embarrassment" about how they handled the pandemic, Jack says. They want it in the history books and forgotten. Joel says this is a grave mistake for public trust — and for public health, given COVID is now a permanent fixture alongside flu season.00:50:50 — Why Excess Deaths Are the Only Honest Metric All other figures are "kind of made up" because attribution methods vary wildly between countries. Excess deaths remain elevated in Australia and most nations.00:51:25 — Children and COVID Bobby Kennedy Jr. removed under-18s from government-supported vaccines in the US. Joel argues this is a disastrous move given mounting evidence that childhood COVID infection leads to higher rates of long-term chronic illness.00:52:47 — Why No Royal Commission? Not just politicians protecting themselves — public health officials and much of the media wanted to avoid scrutiny of their judgments and actions during the pandemic.00:53:32 — The Media's Abdication Jack watched "a lot" of Daniel Andrews's daily press conferences. Only two journalists ever asked pertinent questions: Rachel Baxendale and Leigh Sales. Nobody asked why curfews, why beach arrests, why the disparate impact on tradies and cafe owners while the "laptop class" actually made money working from home.00:56:14 — Andrews's Immense Popularity Joel adds context: Andrews was wildly popular at the time, which partly explains the media's deference — though Jack insists that shouldn't have mattered.00:57:34 — The Curfew Nonsense Curfews were about giving law enforcement the easiest possible environment, Joel says — and should have been acknowledged as such and wound back sooner. Meanwhile, Bondi's wealthy swam en masse while Western Sydney's working-class communities were treated harshly.00:57:59 — The Vaccine Rollout Failure The Morrison government bet everything on AstraZeneca — the non-mRNA, first-available vaccine. Then rare blood-clotting issues emerged (seven deaths, mainly men aged 40–49). Meanwhile, Australia was left waiting for Pfizer and other mRNA vaccines because no other supply deals had been secured.00:59:37 — Omicron Breaks the Pandemic's Back The Omicron variant emerged from South Africa: more infectious but far less lethal. Combined with 95%+ vaccination rates among Australians over 18, it effectively ended the acute phase — though at the cost of entrenched mistrust.01:00:38 — Government Overreach and Broken Trust Jack's core criticism: governments outsourced decision-making to public health officials rather than making political judgments that balanced competing interests. Joel counters that it would have been a "bold move" for politicians with no scientific background to contradict public health advice.01:02:19 — "Just Let It Rip" Was Never an Option The three countries with the highest COVID mortality — Brazil (highest), United States (second), India (third) — were all led by populist governments that largely refused mandates. Letting it rip was devastating.01:03:27 — The ADF Quarantine Scandal Scott Morrison refused to allow ADF quarantine facilities to be used for returning travellers. Instead, people were crammed into hotels with gaps under the doors. Joel recalls the "rubbish bags over heads" episode in Victoria — dark green plastic bags as infection control.01:05:00 — The Inquiry's Recommendations Create a proper Australian CDC. Release expert advice publicly. Better national planning with clear political accountability. And critically: politicians must own the big decisions on freedoms and spending instead of hiding behind experts.01:06:01 — The Next Pandemic There will be another one. If it's a respiratory, airborne pathogen like COVID, similar circumstances will return. Are we ready? Probably not. Will we close the country again? The economic damage — unemployment hitting 7.5% in 2020 — was enormous, even if it recovered to 3.5% by pandemic's end.01:08:06 — Who Was Left Behind? The arts community was inexplicably excluded from JobSeeker and JobKeeper. Meanwhile, the "laptop class" working from home effectively got a 15% pay rise by eliminating commuting costs. Bunnings did very well; so did companies that kept JobKeeper without passing it to employees.01:11:14 — The Human Cost of Lockdowns Public housing towers in Flemington were locked down. Joel recalls one family: an African-Australian single mother with nine children in a two-bedroom commission flat, trapped. Jack calls what happened with schools "disgraceful." But Joel notes the evidence now shows childhood COVID infection has serious long-term health consequences, complicating the retrospective judgment.01:13:59 — Will We Learn Anything? Jack's bleak prediction: the next pandemic is probably far enough away that we'll take no notice of COVID's lessons and make the same mistakes. Joel agrees — we didn't learn from the Spanish flu a century ago either.01:15:51 — Malcolm Roberts and Vaccine Misinformation The One Nation senator claims 70,000 Australians died from COVID vaccines — a figure with no evidentiary support, built by misattributing excess deaths. In reality, mRNA technology is now being deployed as a cancer treatment, showing promise against bowel and pancreatic cancers.01:17:36 — Trust Destroyed If the next pandemic arrives within this generation, governments will face a population that has lost faith. If it takes 50 years, the damage may have faded. Western Australia, meanwhile, locked itself down with negligible deaths and actually loved the isolation — provided the iron ore and LNG ships kept moving.01:20:37 — The Spanish Flu Echo Joel's closing historical note: Australia's response to the Spanish flu in 1919–1921 was nearly identical to COVID — lockdown disputes, police arresting people for not wearing masks, states fighting the newly created federal Department of Health. The whole thing collapsed into acrimony the moment state rivalries flared. A century later, nothing had changed.01:21:48 — Federation as Fatal Flaw Jack adds: the three high-mortality COVID countries (US, Brazil, India) share a feature beyond populist leaders — they're all federations where central government power is limited. When "the emperor is far away and the mountains are high," coordinated pandemic response is nearly impossible.01:23:40 — No Appetite for Truth Jack's final word: nobody wants a proper inquiry. Not politicians, not public health officials, not much of the media. Joel disagrees on the importance — the pandemic's legacy still shapes how Australians think, vote, and trust.Sport01:27:40 — AFL Coaching Carousel Essendon and Carlton both need permanent coaches. Joel asks: is James Hird the right man for Essendon? Jack: 17 other clubs wouldn't give him an interview, but the Bombers may have backed themselves into a corner where appointing him is the only way out.01:28:53 — Merit vs Member Sentiment Rowan Connolly's question: would you take James Hird or John Longmire (five grand finals, one premiership, 60%+ win rate)? The answer is obvious on merit — but members and fans want the fairy tale.01:29:47 — Carlton's Astonishing Revival Three straight wins. Ranked 16th in forward-50 entries a month ago; now second. The game style is unrecognisable — no more bombing the ball to non-existent power forwards. Mitch McGovern's low, flat kick to Patrick Cripps for the match-winner against Geelong was emblematic of the transformation. Seven players aged 21 or younger are now getting games and bringing energy.01:33:18 — FIFA World Cup 2026: Nobody's Excited Expanded to 48 teams, Scotland are going — and a Scot in his 30s told Jack that neither he nor any of his mates (all doing well financially, normally first on the plane) have any interest. Ticket prices are "extraordinary." The final is at MetLife Stadium in New Jersey — which Jack describes as "Waverley on steroids, but even more bleak."01:36:08 — Australia's Draw Socceroos face Turkey first up, then the United States. Jack suggests marketing it as "Gallipoli Round Two." Spain are favourites; England, Brazil, and Germany are in the chasing pack.01:37:06 — Cricket: England v New Zealand, First Test at Lord's Joel runs through New Zealand's likely top seven — Latham, Conway, Williamson, Ravindra, Mitchell, Blundell — noting the first four have all made Test double-centuries. "Just about the best first six in Test cricket." With O'Rourke's express pace and Henry's quality, this is a formidable Black Caps side.01:38:40 — Stump Speech & Next Week Listener mail (including an "exposé of who Jack is") held over for next episode. For the record: Hong Kong Jack's CV includes HSC at Assumption College Kilmore, a stint as a carpenter, a law degree from Melbourne University, stints at Holding Redlich and Slater & Gordon, work as a litigation and immigration lawyer, and an appointment to the Refugee Review Tribunal as a federal cabinet appointee.01:40:39 — Outro Joel thanks listeners for hanging in for an extra ten minutes. Back next week.The Two Jacks is recorded weekly. Send your questions and feedback to the show.

We love to hear from our listeners. Send us a message.In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

By hiding behind "sterile" roadside signs and refusing to let candidate Fiona Hammond speak to the media, the LNP’s hyper-cautious campaign completely lost touch with everyday voters. Discover why modern political machines are so terrified of unscripted moments, and how Labor’s willingness to actually talk to people secured them the win.See omnystudio.com/listener for privacy information.

Things at the LNP are getting spicy, Trump comes up with a White House first and stories of those who've ruined their first date!See omnystudio.com/listener for privacy information.

Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss a landmark collaboration with Acuitas Therapeutics, the lipid nanoparticle specialist whose technology underpinned some of the most successful COVID-19 vaccines ever made. Leire described it as one of the most significant partnerships Genflow has signed, giving the company access to the gold standard in mRNA delivery technology - fully funded by Acuitas, with no cash cost and no dilution to shareholders. The collaboration will combine Genflow's proprietary SIRT6 payload with Acuitas' clinically validated LNP platform, generating preclinical data to support future clinical development and partnering discussions. Leire positioned the deal as a potential inflexion point, transitioning Genflow from a science story into a tangible clinical and commercial opportunity. For more videos like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications so you never miss an update. #GenflowBiosciences #EricLeire #BiotechNews #SIRT6 #mRNA #LNP #Acuitas #BiotechInvesting #HealthcareInnovation #DrugDevelopment #ClinicalTrials #LifeSciences #InvestingNews #ProactiveInvestors

Questions are raised over Australia's visa process, One Nation now leads Labor and the LNP in Queensland. Plus, Moira Deeming joins the show to exclusively discuss her chaotic battle towards securing Liberal preselection.See omnystudio.com/listener for privacy information.

LifeLine Church has had the privilege of journeying in relationship with Lifeline Nehemiah Projects (LNP) in Sierra Leone for 30 years – we’re celebrating this relationship by remembering the story, exploring all the lessons God has taught over the 30 years and sending a team of 13 people out to join the celebrations with LNP in Freetown. This podcast is part of a series on the books of Acts which is supported by periodic ‘reflections’, which consider questions which have been submitted by members of LifeLine Church. To stay up to date with podcasts from LifeLine Church, please subscribe. Shows include: LifeLine Church Sunday Services – a weekly broadcast of the message from our Sunday meeting Evolution Revolution with LifeLine Church – an exploration of how foundational values can transition across generations Reflections on Acts – exploring the application of the practical, faith-filled exploits of the early church in today's context Reflections on Kings 1 & 2 – applying the insights and lessons from these two old testament books to our lives today Kingdom Finance – Jesus talked more about money than about anything else. Why? How do we handle money correctly? Kingdom Relationships – Relationship is core to the character and nature of God…so what does real friendship look like for us? To access a range of resources and supporting material, series on specific topics including Kingdom finance and Kingdom relationships please visit lifelinechurch.co.uk If you prefer to watch, please visit our YouTube channel @LifeLineChurchDagenham where we broadcast our Sunday meeting live at 10.30am. Playlists include: Reflections on Acts Reflections on Kings 1 & 2 Sunday morning talks Testimonies A Pilgrim's Story

This week, President Trump posted on Truth Social that more ICE agents will be present at airports to address the long waits caused by the Department of Homeland Security partial shutdown. Elizabeth Neumann and Harvest Prude join us to discuss this and the ramifications of the shutdown. Then, a Georgia jury convicts a parent whose son murdered multiple people in a school shooting of second degree murder. Shooting survivor Taylor Schumann and breaking news reporter Jack Panyard help us understand these new prosecution strategies. Finally, a Los Angeles court ruled that Facebook, Instagram and YouTube are knowingly creating products that cause addiction and harm to children. Facebook whistleblower Frances Haugen and parent technology coach Krista Boen join to share about these technologies and the implications for families. REFERENCED IN THE EPISODE: Stop Being Anxious About Your Anxiety - Russell Moore ABOUT THE GUESTS: Elizabeth Neumann is a national security expert who has served across three presidential administrations: on the inaugural staff of the White House Homeland Security Council under President George W. Bush, as an advisor to the office of the director of national intelligence during the Obama Administration, and as the Department of Homeland Security's deputy chief of staff and assistant secretary for counterterrorism and threat prevention in the first Trump administration. Neumann is also a national security contributor for ABC News. Harvest Prude is Christianity Today's national political correspondent and a congressional reporter based in Washington, DC. She is a former reporter for The Dispatch and World, having served there as political reporter for their Washington bureau. Taylor Schumann is a writer, activist, and survivor of the shooting at New River Community College in Christianburg, Virginia in 2013. She wrote the book When Thoughts and Prayers Aren't Enough. Jack Panyard is a multimedia journalist covering breaking news, courts, crime, politics, education, and health for LNP and Lancaster Online. He has reported on Jeffrey Epstein's crimes in the podcast Broken: Jeffrey Epstein. Frances Haugen is an advocate for accountability & transparency in social media. In 2021 after becoming alarmed by the choices Facebook was making to prioritize their own profits over public safety, she disclosed tens of thousands of Facebook's internal documents to the SEC and The Wall Street Journal. Since then she has testified in front of Congress and has engaged with lawmakers internationally on how to best address the negatives of social media platforms. Krista Boan is the co-founder and director of culture at the organization Screen Sanity, a non-profit that provides trainings, tools and tips to help communities and families maximize the benefits of technology, while minimizing the negative side effects. GO DEEPER WITH THE BULLETIN: Join the conversation at our Substack. Find us on YouTube. Rate and review the show in your podcast app of choice. ABOUT THE BULLETIN: The Bulletin is a twice-weekly politics and current events show from Christianity Today moderated by Clarissa Moll, with senior commentary from Russell Moore (Christianity Today's editor-at-large and columnist) and Mike Cosper (senior contributor). Each week, the show explores current events and breaking news and shares a Christian perspective on issues that are shaping our world. We also offer special one-on-one conversations with writers, artists, and thought leaders whose impact on the world brings important significance to a Christian worldview, like Bono, Sharon McMahon, Harrison Scott Key, Frank Bruni, and more. The Bulletin listeners get 25% off CT. Go to https://orderct.com/THEBULLETIN to learn more. “The Bulletin” is a production of Christianity Today Producer: Clarissa Moll Associate Producer: Alexa Burke Editing and Mix: Kevin Morris Graphic Design: Rick Szuecs Music: Dan Phelps Executive Producer: Erik Petrik Senior Producer: Matt Stevens Learn more about your ad choices. Visit podcastchoices.com/adchoices

Shownotes are AI slop as usual. It's a week late cause nobody bothered to tell me it was recorded. Apologies for lack of freshness. ---------------------------------------------------------------------------------Jack the Insider and Hong Kong Jack are back for Episode 144, recorded on 12 February. It's Liberal Party leadership spill eve and the boys break down whether Angus Taylor has the numbers to end Susan Ley's tenure — and what sort of baggage he'll carry into the job. From there: a landmark High Court ruling on the Catholic Church's duty of care for survivors of clergy abuse; the protests surrounding Israeli President Isaac Herzog's visit to Australia; the widening Epstein-Mandelson catastrophe engulfing Keir Starmer; the slow collapse of the Washington Post; Japan's election result and its implications for China; and a packed sports segment covering the T20 World Cup, AFL State of Origin, the Rugby World Cup opener, and the Winter Olympics.Show Notes & Timestamps

In this episode, Dr. Kahina Lang, Executive Director and Head of Next Gen Drug Delivery at Merck Group, discusses her pioneering work developing targeted mRNA delivery systems using lipid nanoparticle (LNP) technology. She shares insights on building an internal startup within the world's oldest pharmaceutical corporation, the technical innovations enabling precision medicine, and the future of cell and gene therapies. Tune in for an insightful conversation on how entrepreneurial leadership, digital-first research approaches, and open-innovation models are accelerating breakthrough therapeutics from the lab to the clinic.

Brent Mickelberg, QLD Minister for Transport and Main Roads joined us to let us know what the sitting LNP governments plans are for the Bruce - and he had some very positive updates to share, and timeframes for some major upgrades!See omnystudio.com/listener for privacy information.

The messy fallout of the Coalition's breakup continues this week with Sussan Ley and David Littleproud attempting to weather criticisms of their leadership after the Bondi terror attack. LNP moderate Andrew Wallace speaks to political editor Tom McIlroy about his support for Sussan Ley, and describes her as ‘principled' and ‘tough' under very difficult circumstances. The shadow attorney general also says that he is ‘relatively comfortable' with the hate speech legislation that divided the Coalition, which was passed last week. Politics aside, Wallace talks about volunteering as a surf lifesaver on the Sunshine Coast and is candid about the challenges of being a father of four while serving as a MP

We love to hear from our listeners. Send us a message.In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications. Oakes shares Scribe's engineered CasX platform and epigenetic silencers, preclinical data from its various programs, and why exquisite specificity and low-dose LNP delivery are essential to treating patients safely. They also explore Scribe's partnerships with Sanofi and Lilly, the company's cardiometabolic-first strategy co-developed with Dr. Jennifer Doudna, and Oakes' conviction that genetic medicines can fundamentally reshape healthspan and the future of preventive cardiovascular care.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

The LNP is moving to scrap compulsory preferential voting, a move that could fundamentally shift the balance of power across the state. From lifting developer donation bans to redrawing the electoral map, Gary and Georgia Kondek dive into how these reforms might impact the 2028 election and beyond.See omnystudio.com/listener for privacy information.

3 - The LNP's love-hate relationship by Australian Citizens Party

For a second time since the election the Coalition has split. The Nationals walked out after a number of its senators crossed the floor to vote against hate speech laws this week.  The Liberals and opposition leader Sussan Ley sided with the government to pass the legislation, but key Nationals raises concerns about the rushed process and the impact on free speech. So, is this a moment of real change in conservative politics and could One Nation pick up a few more members? Today, David Speers, the ABC's national political lead and host of Insiders, on how the marriage fell apart once again. Featured: David Speers, ABC national political lead

Opposition Leader Jared Cassidy revealed why he believes the LNP’s 20-year grip on Brisbane is slipping and why he's considering a run for Lord Mayor. He argued that basic services like road maintenance and bin collection are failing while the current administration focuses on "mini-state government" vanity projects.See omnystudio.com/listener for privacy information.

AI slop as usual. Enjoy! In this wide-ranging episode, the Two Jacks dissect Australia's improved bushfire response amid the Victorian fires, the newly announced royal commission under Justice Virginia Bell, Kevin Rudd's resignation as US Ambassador, escalating unrest in Iran and Venezuela, Ukrainian paramilitary intrigue, US political and economic turbulence, and a detailed cricket analysis covering the Australian summer and England's ongoing struggles.0:00–0:27IntroductionOpening banter and Hong Kong theme music0:27–8:00Australian BushfiresDiscussion of recent Victorian fires around Alexandra and Longwood; praise for improved evacuation technology, CFA coordination, and community heroism since Black Saturday8:00–11:09Kevin Rudd's ResignationAnalysis of Rudd's departure as US Ambassador, his public spat with Elon Musk, and new role as Asia Society President11:09–20:50Royal Commission AnnouncementDeep dive into Virginia Bell's appointment, scope of the inquiry (governance failures, anti-Semitism, extremism), government delays, and potential security secrecy measures20:50–31:00Australian Political LandscapePolling analysis, Labor vs. LNP, One Nation's resurgence, upcoming South Australian election, and protest voting dynamics31:00–36:00US Economic & Political TurmoilVIX volatility, Jerome Powell's position, interest rate debates, and Trump administration's policy impacts36:00–45:00Iran Protests & Regional UnrestEconomic collapse (Rial devaluation), spreading regional protests, regime fragility, Western hesitation on intervention, and BRICS dynamics44:00–50:00Venezuela CrisisMaduro's grip on power, US sanctions, paramilitary threats, opposition struggles, and regional destabilization50:00–56:00US Domestic IssuesMinnesota shooting incident, police conduct debates, First Amendment tensions, and body-camera footage controversies56:00–1:00:00Ukraine Conflict UpdateDenis Kapustin's alleged drone strike death, neo-Nazi paramilitary links, GUR intelligence operations, and misinformation battles1:00:00–1:09:00European & UK PoliticsStarmer's Labour struggles, potential leadership challenges, Macron's position in France, and broader European political shifts1:09:00–1:22:00Cricket AnalysisAustralian summer review, BBL performances, emerging talent (multicultural pipeline), England's coaching chaos, disciplinary issues, and 2027 Ashes preview1:22:00–EndWrap-Up & Listener EngagementFinal thoughts and call for listener feedbackKey Topics CoveredAustralian Bushfires: Improved CFA response, evacuation technology, community resilience in Alexandra and LongwoodRoyal Commission: Justice Virginia Bell's appointment, scope including anti-Semitism and governance failures, procedural secrecyKevin Rudd: Resignation as US Ambassador, Musk feud, Asia Society appointmentIran: Economic devastation, hyperinflation, regional protest spread, US/Western response optionsVenezuela: Ongoing instability, Maduro's regime, sanctions impactUkraine: Denis Kapustin saga, paramilitary operations, GUR intelligence successesCricket: Australian talent depth, multicultural recruitment, England's discipline and coaching woes, 2027 Ashes outlookBRICS: Economic bloc now exceeding US+EU GDP, geopolitical implications

We love to hear from our listeners. Send us a message.In Episode 118, Host Erin Harris talks to Alexander Cryer, Ph.D., Instructor in Medicine at Mass General Brigham, about a proof of concept strategy that reprograms tumor cells with mRNA lipid nanoparticles to overactivate the cGAS-STING pathway, forcing cancer cells to produce and export large amounts of the innate immune agonist cGAMP to stimulate surrounding immune cells and drive anti-tumor immunity. Dr. Cryer explains the basic biology of cGAS-STING and how his team restored this pathway in tumor cells and leveraged intratumoral LNP delivery to overcome nucleic acid delivery and targeting challenges. He also discusses future directions, the need to move beyond intratumoral administration with more targeted systemic delivery, and the broader concept of turning the tumor's own abundant cell population and evolutionarily conserved innate immune pathways into therapeutic allies rather than obstacles.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Despite the LNP's "adult crime, adult time" campaign, recent data shows that only 1 in 8 youth offenders sentenced as adults are actually serving time behind bars. Criminologist Terry Goldsworthy joined Ben Davis on 4BC Drive to suggest that without removing judicial discretion through mandatory minimum sentencing, these leniency trends will continue.See omnystudio.com/listener for privacy information.

Tom and The Griff marvel at Max Chandler-Mather getting a fair run in an Australian newspaper!? Next, Tom is joined by Sarah-Hanson Young, Greens senator for South Australia! First up, the state of play and then a look at a recent Crikey article featuring unhappy Greens staffers (19:01). Then, with the LNP ditching net zero, and the country seemingly unbothered that Labor has effectively ditched it, what is going on? (38:39) ---------- Just released on Patreon - “Making fun of political ads with Wil Anderson, live at Comedy Republic” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over EIGHTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Max Chandler-Mather article - https://www.smh.com.au/politics/federal/max-chandler-mather-on-the-greens-his-election-loss-and-his-return-to-politics-20251105-p5n82t.html Crikey staffer article -https://www.crikey.com.au/2025/11/07/the-greens-australia-climate-environment-gaza-cost-of-living/Meanjin/Brisbane people come see Tom at GoodChat this Thursday November 20th -https://www.eventbrite.com.au/e/tom-ballard-live-tickets-1471601372319 See Tom live on tour in Melbourne Fringe and Geelong - https://comedy.com.au/tour/tom-ballard/ Produced by Michael Griffin https://www.instagram.com/mikeskillz Listen to Floodcast for more left green discussion about Aussie politics produced by The Griff -https://linktr.ee/floodcastau Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

The Liberal Party has officially said farewell to net zero by 2050. Joined by Amy Remeikis, we're unpacking the decision, what it'll mean for the libs moving forward and how their leader, Sussan Ley, has lived to see another day at the head of the table. Plus, there's an urgent call to ban industrial trans fats from Australia's food supply over concerns of their links to cardiovascular issues. We're on the case about what trans fats actually are, why they're hidden and how Aussies can spot them at the supermarket. And in headlines today, Newly released congressional documents show Jeffrey Epstein called Donald Trump “borderline insane” in private emails before Epstein’s death; The family of murdered grandmother Vyleen White has slammed the 16-year maximum sentence for her 16-year-old killer; Reforms to improve safety in childcare and early education could be implemented nationwide by the end of the year; Psychiatrist Dr Daniela Vecchio has been named 2026 Australian of the Year for Western Australia for her work treating gaming addiction in young people. THE END BITS Support independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Hosts: Taylah Strano & Tahli Blackman Guest: Amy Remeikis, Chief Political Analyst at The Australia Institute & Contributing Editor at The New Daily Audio Producer: Lu Hill Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

[Ad]  Support our show and yourself by supporting our two great sponsors! Go to https://piavpn.com/OTHERSIDE to get 83% off Private Internet Access with 4 months free!   AND D-I-Y Your Patio, Carport, Deck, Pergola and more with SmartKits at smartkits.com.auThis week on  THE OTHER SIDE...   (Ep 433  w/c Fri 7 November 2025)  Segment 1 -  NET ZERO BRAINS   With energy prices rising 24% in a year, most Aussies are thinking twice about why a country as small as ours is bothering with Net Zero at all. And the issue is tearing the major conservative parties apart.   Segment 2 -  LIBERAL REFORM BEGINS    Liberal-National party coalition support continues to plummet to record lows. One Nation has surged to a record 15%.  But not everyone wants to jump ship. Two prominent LNP elders have decided to start their own LIBERAL REFORM movement at ReclaimTheDream.com.auSegment 3 -  SAVING THE LIBERAL PARTY    24%. That is the abysmal level of support left for the main conservative political party coalition in Australia, the Liberal-National parties, according to Newspoll.  How do members save their party?Segment 4 -  WHY POLLIES ARE SO GUTLESS  When Robert Menzies launched his new Liberal Party in 1946, he had 60,000 members when the population was ~6million. So the Liberals & Nationals should have around 280,000 members today. But they only have a tenth of that. We discuss why with our expert panel. Segment 5 -  SOCIALISM RISES     It was Election week in America this week. Two states elected new Governors and New York City elected a new mayor and it was an ALL Democrat victory spree. The new NYC mayor is a radical leftist. We discuss why - and what it means for the future. Help us build a whole new world of Aussie media! Support us by joining THE EXCLUSIVE SIDE at https://www.othersidetv.com.au/Follow us on X  @OtherSideAUSSubscribe NOW on YouTube @OtherSideAUSSupport us - Support our Sponsors - PIAVPN.com/OtherSide and  smartkits.com.auSupport the showJoin The EXCLUSIVE Side at www.OtherSideTV.com.au and help us revolutionise Aussie media! The Other Side is a regular news/commentary show on YouTube @OtherSideAus and available to watch FREE here: https://www.youtube.com/@OtherSideAus Follow us on X @OtherSideAUS

The Coalition has sunk to its worst approval rating in 40 years of Newspoll, while leader Sussan Ley has plunged further into the negatives. Can she – and the party – continue? You can read more about this story, plus see photos, videos and additional reporting, on the website or on The Australian’s app. This episode of The Front is presented and produced by Kristen Amiet and edited by Lia Tsamoglou. Our regular host is Claire Harvey and our team includes Tiffany Dimmack, Joshua Burton, Stephanie Coombes and Jasper Leak, who also composed our music.See omnystudio.com/listener for privacy information.

Ben was joined by Matt Dennien from the Brisbane Times to discuss the Queensland state redistribution, specifically the first round of submissions. The conversation focuses on the Labor and LNP submissions, and also run through some of the other public submissions. This podcast is supported by the Tally Room's supporters on Patreon. If you find this podcast worthwhile please consider giving your support. You can listen to an ad-free version of this podcast if you sign up via Patreon for $8 (plus GST) or more per month. And $8 donors can now join the Tally Room Discord server.

Brad Battin coming to you live from the scene of the crime. Emerald and Tom recap the mayhem down in the Tasmanian parliament (7:04), as LNP takes government and now-former Labor leader steps on a series of rakes and somehow it’s those dastardly Greens’ fault. Next up, there’s ‘March for Australia’ rallies being organised for August 31st, and they are a big dog-whistle by all the worst people in the country (24:25). Then they are joined by economist and Executive Director of The Australia Institute Dr Richard Denniss to unpack last week’s Productivity Roundtable (39:44). What is the definition of insanity? Finally, a call to action (1:14:09). ---------- Just released on Patreon - “Posting & Boasting from WA ft. Gerard Mazza” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SEVENTY-FIVE past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Follow Richard Denniss - https://australiainstitute.org.au/expert/richard-denniss/ https://bsky.app/profile/richarddenniss.bsky.social Read ‘Dead Centre: How Political Pragmatism is Killing Us’ out now in Vantage Point - https://australiainstitute.org.au/store/dead-centre-vantage-point-issue-2 Richard’s tour -https://australiainstitute.org.au/events/dead-centre-richard-denniss-book-tour/ National March for Palestine - today Sunday August 24th https://www.greenleft.org.au/content/august-24-join-nationwide-march-palestine Produced by Michael Griffin https://www.instagram.com/mikeskillz Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

Good news! The new bubble machine works! Bad news… no one's here to see it.As discussed on last week's show, Paul Kramer ​⁠ @autokennel  is having major surgery to remove the bone cancer in his leg. J is at hospital with Paul's family so we get an LNP flashback.Tonight, we're flashing back to an early episode of Life with the Ryan's revisiting a conversation with SoCal Porsche and Alfa Romeo legend Chuck Miller.Chuck passed away a few months ago and is missed by a great many. We were so lucky to hear some of his first-hand experiences, living the historic SoCal car culture we all celebrate today. Hopefully this video captures Chuck's spirit and reminds everyone of his zest for life & driving.. RIP. We love you Chuck. Thank you for the memories and for always being kind.And thank YOU for being with us. Back next week LIVE @ FIVE. Get those comments ready!

Inmitten einer Urlaubspause kommen wir noch mal zusammen und fegen ein paar Nachrichten zusammen und gehen auch noch einmal auf ausgewähltes KI-Feedback der letzten Sendung ein. Linus hat die neue Minkorrekt-Show besucht und macht sich seine Gedanken zur Rolle von Wissenschaft in der aktuellen Gesamtlage. Wir sprechen dann noch über die Stellen für Lehrkräfte in Baden-Württemberg, die einem IT-Fehler zum Opfer fielen, die von der Trump-Regierung erzwungene Beerdigung der UK-Pläne, Verschlüsselung zu zerstören, der EU-Petition "Stop Killing Games", dem Ende von CUII und über Funklöcher und Datenelche. LNP macht dann voraussichtlich bis Mitte August eine Pause.

Tonight in the Playset...RIP Ozzy. RIP Late Show. J and Brandon's new podcast...Then joins SoCal Porsche legend, engine builder, recent-widower Marco Gerace from TLG AUTO. How's the 996 cup car? What's happening with TLG?? Where are Aimee's clothes???Mazda factory driver (and former LNP intern) Joey “The Stiglette” Andrew's has had quite an interesting season, including a roll-over at Road Atlanta. We recount the literal ups and downs. of his journey.Plus Babes in Classics, MC3 films and YOU in the comments, all night long.Got a question for Marco or Joey? Drop them below or join us LIVE @ 5 Pacific on the show!Thank you for being with us! #latenightplayset

As Pennsylvania’s budget remains more than two weeks overdue, this week’s Journalist Roundtable takes a closer look at the gridlock in Harrisburg—and what voters say they want their leaders to focus on. Joining the conversation are Jordan Wilkie, Regional Democracy Reporter for WITF and LNP, and Stephen Caruso, State Capitol Reporter for Spotlight PA.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Ying Tam, Chief Scientific Officer at Acuitas Therapeutics, discusses the company's role in delivering the first personalized CRISPR gene editing treatment to an infant with CPS-1, achieving treatment in just six months from diagnosis. Tam shares insights on evolving lipid nanoparticle technology beyond COVID vaccines, including LNPs that allow for next-generation immune-targeting delivery that is 10x more potent, and progress in delivering genetic medicines to stem cells and solid tumors. He also addresses the challenges of repeat dosing, a new biodegradable LNP formulation, and expanding genetic medicine beyond the liver to treat blood disorders and cancer.

Does the Liberal party need a quota for women? The party faces a stark reality - just six women among 28 elected officials, we examine whether quotas are the answer to fixing the Liberal Party's gender problem. Plus a major update in the case of the accused college share house murderer, which could see him avoid the death penalty. And in headlines today More than 1300 incidents have been reported as heavy rainfall and strong winds lash the NSW coast; The US Senate has passed President Donald Trumps big tax and spending bill; US President Donald Trump has threatened to pull all of Elon Musks subsidies saying it would make him pack up and head back to South Africa; The jury in the Sean Diddy Combs sex trafficking trial has asked to review parts of Cassie Ventura's testimony; Managers at the British hospital where Lucy Letby murdered 7 infants have been arrested on suspicion of gross negligence manslaughter THE END BITSSupport independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Hosts: Taylah Strano & Claire Murphy Guests: Jess Wang, NewsWire Federal Politics Reporter Audio Producer: Lu Hill Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Even Barnaby Joyce did more work as a fake envoy than Peter Khalil! After some bafflement about Tasmania, Emerald and Tom unpack Senator Dorinda Cox, the very first ever guest on Serious Danger, and her defection to Labor this week (11:20). What an r-slur (rat)! Then, a Guardian piece looks at what went wrong for the Greens at the federal election (49:56). Was Advance the Greens-killer or part of the reason the LNP became so toxic? No call to action this week, so a reminder from Griff not to search google for “Kevin Rudd Jeffrey Epstein”. ---------- Just released on Patreon - “Inside The Greens #9 : CPRS, Rudd-Gillard & the 2010 election” The show can only exist because of our wonderful Patreon subscriber’s support. Subscribe for $3/month to get access to our fortnightly subscriber-only full episode, and unlock our complete library of over SEVENTY past bonus episodes. https://www.patreon.com/SeriousDangerAU ---------- Links - LIVE IN BRISBANE - JUNE 21ST - ON SALE NOW WITH SPECIAL GUEST ELIZABETH WATSON-BROWN - https://www.eventbrite.com.au/e/serious-danger-w-emerald-moon-tom-ballard-live-in-brisbane-tickets-1384636748789 The Guardian’s analysis of Greens election results - https://www.theguardian.com/news/ng-interactive/2025/jun/02/what-went-wrong-for-the-greens-in-the-australian-election Produced by Michael Griffin https://www.instagram.com/mikeskillz Follow us on https://twitter.com/SeriousDangerAU https://www.instagram.com/seriousdangerau https://www.tiktok.com/@seriousdangerauSupport the show: http://patreon.com/seriousdangerauSee omnystudio.com/listener for privacy information.

This week, Stephen Donnelly covers election results in the ACT, the NT, and Western Australia.First-time guest Louise Crossman is a Canberra based political strategist and former president of ACT Labor. She and Stephen discuss the ACT results, including the rise of independents and how Labor almost lost the seat of Bean.In the Northern Territory Ryan Neve explains how turnout for Labor in remote communities ensured big swings in Lingiari, and the impact a popular CLP Chief Minister had on the race in Solomon. Finally in Western Australia Priya Brown revisits her original predictions and wagers - Bullwinkel's surprising swing to Labor did indeed signal a nationwide triumph for Labor - even if it hurt Priya in the pocket. Join us for this joyful episode - and don't forget to book tickets for our live show if you live near Melbourne!May 29, 7pmThe Toff in Town52 Swanston St, Melbourne VIC 3000Team Leaders and Campaign Organisers - Message Us for 2 x Free TicketsCanvassers- Book Tickets Here.CHAPTERS:00:00 Episode Start03:01 The ACT06:26 Bean14:19 The Senate23:26 The NT24:41 Solomon29:19 Lingiari34:15 Territory Election40:11 Western Australia46:39 Bullwinkel49:22 Pearce52:58 Canning56:51 Tangney01:02:11 MooreNew episodes every Friday.Join our Patreon: https://www.patreon.com/c/SociallyDemocraticFollow Us on Socials:Facebook (https://tr.ee/9jGIOy)Instagram (https://www.instagram.com/sociallydemocratic)LinkedIn (https://tr.ee/YxyYJh)Twitter (https://x.com/SocialDemPod)Bluesky (https://tr.ee/EqdapC)YouTube (https://www.youtube.com/@DunnStreet)The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the showNew episodes every Friday. If you like the show, rate and review us on your favourite podcast app. Follow Us on Socials: Facebook (https://tr.ee/9jGIOy)Instagram (https://www.instagram.com/sociallydemocratic)LinkedIn (https://tr.ee/YxyYJh)Twitter (https://x.com/SocialDemPod)Bluesky (https://tr.ee/EqdapC)YouTube (https://www.youtube.com/@DunnStreet) The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au

Nuclear power - and political power games - break up the Liberal-National Coalition. National editor Dennis Shanahan tries to make sense of David Littleproud’s big breakup. Find out more about The Front podcast here. You can read about this story and more on The Australian's website or on The Australian’s app. This episode of The Front is presented by Claire Harvey, produced by Kristen Amiet and edited by Joshua Burton. Our team includes Lia Tsamoglou, Tiffany Dimmack, Stephanie Coombes and Jasper Leak, who also composed our music. See omnystudio.com/listener for privacy information.

Hi Social Democrats,We're taking your favourite centre-left podcast out of the studio for our first live audience recording — and you're invited.Join us to celebrate the historic landslide victory of the Albanese Labor government and the spectacular downfall of the Liberal Party.When: 7:00 pm, Thursday 29 May (doors open 6:15) Where: The Toff, 2nd Floor, Curtin House, 252 Swanston Street, Melbourne Tickets: $15 + booking fee – Limited to 110 seats. Book early to avoid missing out! Free entry for ‘Campaign Organiser' level Patreon members & a plus one. Email grace@dunnstreet.com.au to put your name on the door.Join host Stephen Donnelly and our special guests David Feeney (Westgarth Primary booth captain), Jessie McCrone (former Andrews Deputy Chief of Staff), Benita Kolovos (Victorian State Correspondent, Guardian Australia), and Reed Fleming (former Andrews & Ardern Digital Director) to unpack: How Labor won and why it mattered The Liberal Party's collapse Media hits and misses The digital strategy that helped deliver victoryPlus audience category nominationsWhether you're a political tragic or just want to keep bathing in the warm waters of victory, this special night is for you.Secure your seat now and be part of the celebration: BOOK YOUR TICKETS HERE.See you at The Toff,The Socially Democratic TeamSupport the showNew episodes every Friday. If you like the show, rate and review us on your favourite podcast app. Follow Us on Socials: Facebook (https://tr.ee/9jGIOy)Instagram (https://www.instagram.com/sociallydemocratic)LinkedIn (https://tr.ee/YxyYJh)Twitter (https://x.com/SocialDemPod)Bluesky (https://tr.ee/EqdapC)YouTube (https://www.youtube.com/@DunnStreet) The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au

Welcome to the Personal Development Trailblazers Podcast! In today's episode, we get real about the storms we face and the strength it takes to rise above them.Ethan A. Poetic, a native of Coatesville, PA, now resides in Lancaster, PA. He is the CEO & Founder of Ethan A. Poetic, LLC, empowering people to overcome adversities, life's challenges, and hardships. After surviving a near-fatal car accident and high-risk surgery, he was declared a Walking Living Miracle.Ethan is a Keynote Speaker, Life Coach, Mentor, Mental Health Advocate, Self-Published Author, Certified Mediator, and Restorative Justice Facilitator. He inspires youth and adults through school programs, community events, and public speaking, drawing from his own experiences with poverty, single-parent upbringing, and the need for positive leadership.He's been honored with numerous awards and recognitions, including Pennsylvania Commonwealth Citations, a Proclamation from Lancaster City, features on WGAL TV, CBS 21, 6ABC News, LNP, WFMZ TV, and WiTF Radio, and the NAACP Community Engagement Award. He also received the Distinguished Alumni Award from HACC.Ethan's autobiography, “The Inspirational Story of Ethan A. Poetic,” is available in print, eBook, and audio on Amazon, Audible, Apple, Spotify, Target, Walmart, and more.Connect with Ethan Here: https://www.linkedin.com/in/ethanapoetic1/https://www.facebook.com/ethan.vaughn2/https://www.instagram.com/ethanpoetic23/https://www.youtube.com/@Ethanpoetic23https://www.tiktok.com/@ethanpoetic23https://ethanspeaks.com/Grab the freebie here: https://6abc.com/philly-proud-ethan-a-poetic-car-crash-survivor/14302428/===================================If you enjoyed this episode, remember to hit the like button and subscribe. Then share this episode with your friends.Thanks for watching the Personal Development Trailblazers Podcast. This podcast is part of the Digital Trailblazer family of podcasts. To learn more about Digital Trailblazer and what we do to help entrepreneurs, go to DigitalTrailblazer.com.Are you a coach, consultant, expert, or online course creator? Then we'd love to invite you to our FREE Facebook Group where you can learn the best strategies to land more high-ticket clients and customers. QUICK LINKS: APPLY TO BE FEATURED: https://app.digitaltrailblazer.com/podcast-guest-applicationDIGITAL TRAILBLAZER: https://digitaltrailblazer.com/

The new Liberal leader Sussan Ley has promised a fresh approach after the party's disastrous result in the federal election. But will the first female leader of the party really be able to bring it back from the brink and build a policy offering that's attractive to voters? Today, host of ABC TVs 7.30 Sarah Ferguson on the future of the Coalition's nuclear power plan and Labor's factional stoush that saw two ministers axed.  Featured: Sarah Ferguson, host of 7.30

A new Attorney-General, Plibersek demoted, Dreyfus and Husic to the backbench: the thinking behind Anthony Albanese’s reshuffle - and who’ll be new Liberal leader? Find out more about The Front podcast here. You can read about this story and more on The Australian's website or on The Australian’s app. This episode of The Front is presented and produced by Claire Harvey and edited by Tiffany Dimmack. Our team includes Kristen Amiet, Lia Tsamoglou, Joshua Burton, Stephanie Coombes and Jasper Leak, who also composed our music. See omnystudio.com/listener for privacy information.

Listeners! It' election day and I cannot be bothered so it's AI shownotes this week. Enjoy! Hosts: Joel Hill & Dave (Cooker Watcher Supreme)(00:00:00) Introduction & WelcomeJoel welcomes listeners and introduces guest host Dave, replacing Jack the Insider.Shoutout: CB Co Beer for election night viewing. Mention of a competition involving a boat trip.Election Calls to Action:Vote 1 Fiona Patton in the Victorian Senate, preference 2 Purple Pingers.(00:01:48) Tinfoil Tales Follow-Up: The Next Pope?Discussion on cooker theories about the next Pope (King Charles?).Lindsey Graham's tweet suggesting Donald Trump for Pope.00:02:38 Dave reads the tweet.Trump's blue suit vs. Obama's tan suit controversy revisited.Brief thoughts on the late Pope's legacy and potential successor.(00:04:37) Dave's Cooker Report: Cessnock & CPACDave attended a meeting with Joel Jammal ("Eyebrows") in Cessnock (his 8th visit).Jammal debriefed the local unnamed "Freedom Group" (often linked to One Nation) on his CPAC trip.Local Candidates Present:Stuart Bonds (One Nation candidate for Hunter).Jennifer Stefanak (Trumpet of Patriots Newcastle) - Flat Earther, aliens are fallen angels, won NCAT case after dismissal from child services. Not allowed to speak despite attending.Mysterious Host: Christine Stevens, credited by Jammal as "brains behind the Wollongbae Road campaign" (a local road widening project used by cookers).Stevens now campaign manager for Stuart Bonds (referred to as "boss"). Possible links to broader far-right organising.Joel Jammal's Gifts: Rolled-up maps for Cessnock's 6 cooker councillors showing ALP vs. Voice 'No' vote intersections. Maps available for purchase from Jammal.Jammal's CPAC Trip: Won the trip via the "Shark Bites Pitching Contest" at CPAC Australia (Sky paywall).Winners expected to produce content upon return.Included a communication seminar with Steve Bannon.Stuart Bonds' Candidacy (Hunter):Odds discussed ($10 on Sportsbet).Labor's Dan Repacholi favoured ($1.15).Bonds' history: 21% primary in 2019, left One Nation, rejoined. Consistent far-right vote in the region.Bonds' desire to "start a conversation about coal mining" (already ongoing).Discussion on Labor's telehealth plan and cooker opposition.(00:24:07) Trumpism & Dutton's CampaignDiscussion on the "blueprint for Trump 28".Chris LaCivita (Trump advisor) reportedly helped Peter Dutton's campaign. Joel questions the effectiveness given global trends.Mainstream media's difficulty rallying behind Dutton.(00:25:52) Cooker Report Part 2: Gosford & MyPlaceDave attended the Lisa Bellamy independent campaign launch in Gosford.Follow-on from "Coasties Who Care" (MyPlace environmentalist council ticket).Shadowy Figure: Kate Mason (anti-renewable circuit, IPA/Advance events). Launched Bellamy's campaign.Campaign barely mentions climate change, focuses on opposing Aboriginal Land Council developments.Key Figures on Stage:Jake Cassar (musician, prepper).Lisa Bellamy (MyPlace coordinator, seen at Convoy with Kate Mason).Vicki Burke (MyPlace food/water security organiser, believes in aliens/other planets).Group suggests increased One Nation vote would benefit them. Bellamy received ~3000 votes previously.Kate Mason's Agenda: Reshaping the environment movement to focus on conspiracies (15-min cities, anti-meat).Shapeshifted from anti-vax (IMOP) -> Voice 'No' -> Anti-artificial food/Bellamy campaign.Significant Telegram following despite "gobbledygook" posts.Rally vs. Darkinjung Land Council/Woolworths Development: Focus remains on Land Council projects. Racist undertones ("love the land as much as we do").Links to Garingai (now potentially split/rebranded). NRL Welcome to Country discussed.Jake Cassar Deep Dive: Constant self-promotion, minimal concrete environmental vision beyond opposing the Land Council. Attacks Labor/Greens. Right-wing presence at events. Ballarat missing person search (found dog with SES). Yowie encounter at Woy Woy tip. Lack of accountability in Facebook environmental groups (anti-immigration/Aboriginal rhetoric).(00:40:33) Monica Smit's Private Prosecution of Dan AndrewsMonica plans a private criminal prosecution against Dan Andrews (and Jacinta Allan).Website Quote: "The wait is over righteous justice begins now" - Monica Smit.Topher Field involved as cheerleader/promoter.Basis: "New evidence" (Document 34 FOI email) allegedly showing curfew decision made before consulting CHO Brett Sutton. Implication: tyranny, not health advice.Joel suggests it was likely capitulation to police enforcement ease.Fundraising: Claimed $124,605 raised (via manually updated widget). Monica paid herself $1000/week stipend already.Monica's Justification ("Why me?"): Stood toe-to-toe and won, relentless energy, prison time (refused bail), won appeal, resisted database handover, won unlawful arrest case (appealing costs decision), claims past refund integrity, lives simply, no distractions (children/friends).Bender (@SpambotX) Twitter Thread: Brutal takedown of Monica as a "despicable con woman".Highlights Consumer Affairs conviction ($66k pocketed from unregistered fundraiser).Accuses Topher Field of seeking a cut.Details legal failures, self-orchestrated "martyrdom", $250k legal bill after rejecting settlement.Criticises "journalism" and book ("Cell 22").Predicts prosecution failure and abandonment once donations dry up.Bender's Legal Analysis (Round 2):Private prosecution (Crimes Act s 321) needs prima facie case, not conspiracy.Document 34 likely inadmissible hearsay.Misconduct charge needs proof of knowing, malicious law-breaking (R v Quach).Lockdowns upheld (Loielo v Giles), backed by Public Health Act & CHO advice.DPP can shut down frivolous cases (Public Prosecutions Act s 22).Previous treason case tossed out.Criticises fundraising transparency (Fundraising Act 1998), $52k/year salary.Highlights past legal issues (incitement charges dropped, health order conviction, Judge Tran's comments).Past Precedent: 2021 private prosecution for treason (Anthony Herman) recalled - chaotic online hearing.Monica's Timeline & Updates:Initial plan: Assemble legal team by April 24, first meeting April 30.Reality (May 1): No team announced. Video claims it will take "a few weeks" to pick lawyers.Met with a lawyer ($500/hr, 2 hours booked).Posted picture near a waterfall instead of legal updates ("reset and reload").Now targeting Jacinta Allan as well.Promises refund of remaining balance if no prospect of success.Discussion on cooker lawyers (Matouk, Buckley). Monica's motivation seen as attention/clout chasing.(01:17:54) Return to The Cali (Caledonian Hotel, Singleton)Dave attended Pauline Hanson & Stuart Bonds event ($20 lunch that never happened).Low turnout (~45 people in beer garden). Regulars, pensioners, Chris Sky filming, James Ashby present.Stuart Bonds Guardian article discussed (misogyny, anti-vax, "Little Hitlers"). Worn as badge of honour.Homeschooling attempt due to "woke trans agenda".Red Ensign described as "real flag".Unregistered campaign trailer incident.Pauline Hanson: Speech built to "greatest hits" (Aboriginal industry). Mumbles less the longer she speaks.Cali Update: Corruption Whistleblower book sold at bar (credit card accepted). Eureka beer on tap (FJB beer rebranded/gone?). Frenchies brewery connection? Pub seems to be returning to normal operations, but Red Ensign still flies. Food looks good, beer selection poor (Lion Nathan). No coal miners attended the event despite Bonds' background.(01:36:30) Candidates Forum: Patterson (Port Stephens)Dave attended forum; ABC filming due to anti-wind turbine mob presence.Low turnout of protesters (~5 loud individuals). Meryl Swanson (Labor incumbent) well-prepared.Marginal seat: Libs (Lawrence Ancliffe), aligned Independent, One Nation, Trumpet, Family First running against Swanson.History of intimidation (boat incident during Mayoral campaign).Betting odds discussed (Labor $1.66, Coalition $2.37). YouGov poll (Labor 51.8%).Irony: Libs proposed nuclear plant at Port Stephens in 2007.Bizarre Moments:Trumpet candidate Peter Arena: Wind turbines interfere with missile detection; mentioned fighting audience member over wife littering.(01:42:37) Billy Bay vs GAP Feud UpdateDr. William Bay told people not to vote for GAP (Great Australian Party) despite running for them.Rod Culleton's response.Billy Bay's letter to Culleton: Mock SovCit style ("Office of Vexatious Litigants and Spiritual Audits"), demands apology, foot kissing, $8 trillion. Full of threats (librarian grievance, livestream in lab coat, seizing karma balance). Written on GAP letterhead.Feud background (payment disputes) covered previously by Tinfoil Tales.(01:46:51) Amelia Hamer (Liberal, Kooyong) vs The PeopleRecap: Fake renter scandal (owns 2 properties + trust fund beneficiary).A-Frame sign spamming controversy vs Monique Ryan (Teal MP).Council imposed one-sign limit due to safety/obstruction complaints.Liberals took council to Supreme Court over implied freedom of political communication.Court upheld freedom but allowed council safety enforcement (opaque outcome).Likely outcome: confrontations over sign placement. James Patterson claiming victory. Joel predicts local backlash.(01:51:08) Election Odds & PredictionsSportsbet: Labor $1.05, Coalition $9.50.YouGov: Labor 53 / Coalition 47 (2PP). Projecting 84 seats for Labor (75 needed for majority).Dickson (Dutton's seat): YouGov 50.2% LNP / 49.8% ALP. Sportsbet has Dutton favourite ($1.28 vs $3.35).Joel laments betting ban but expresses optimism for Labor win, potential Dutton loss.(01:53:29) Wrap Up & OutroJoel thanks Dave for his "invaluable" and "brave" cooker reporting.Standard Patreon plugs etc. skipped.Sign off & enjoy the election.

AI shownotes again. I'm sure they are totally accurate. Recorded: ANZAC Day (Australian Public Holiday)Hosts: Jack the Insider & Hong Kong JackIntroduction & ANZAC Day Reflections (00:00:01 - 00:01:17)Jack the Insider welcomes listeners to Episode 111, recorded on ANZAC Day.Mention of an interruption at the Melbourne Dawn Service involving neo-Nazi Jacob Hersant.Introduction of Hong Kong Jack.Hong Kong Update & Australian Politics (00:01:17 - 00:10:05)Hong Kong Exodus: Hong Kong Jack notes 2.2 million people left Hong Kong over Easter.Jacob Hersant Incident: Further discussion on the neo-Nazi escorted from the Shrine of Remembrance.Rise of Neo-Nazism & Fringe Candidates: Jack the Insider discusses the history (Jim Sallium) and current state of far-right politics, including candidates with criminal convictions (Rod Culleton, Dixon candidate) potentially running despite Section 44 eligibility issues.Section 44 Cases: Mention of Phil Cleary and a Greens candidate ("secret New Zealander").YouGov Poll Analysis:Labor: 33.5%LNP: 31%Greens: 14%One Nation: 10.5% (up significantly from ~5% in 2022)TPP: 53.5% (Labor) / 46.5% (LNP)Preference Flows: Discussion on One Nation's decision to preference LNP and historical preference flows to Labor. Challenges for minor parties getting How-To-Vote cards distributed (comparison to Democrats).Election Analysis & Predictions (00:10:05 - 00:20:42)Declining Two-Party System: Combined Labor/LNP primary vote down from the last election.LNP Strategy Critiqued: Jack the Insider criticizes the LNP for not adapting post-2022 election, particularly regarding teal seats and climate change.Campaign Trail: Albanese campaigning in Liberal marginals; Dutton's comments on Melbourne safety.Election Outcome Predictions:Jack the Insider: Labor majority (around 76-80 seats).Hong Kong Jack: Labor minority.Liberal Campaign Issues: Comparison to Latham's 2004 campaign, social media mishaps ("muppet heads"), vehicle emissions policy backflip.Betting Odds: Discussion on the shift in betting markets, favoring Labor.Early Voting: Debate on the merits and drawbacks of pre-polling, referencing Darren Hinch and Imre Selizynski's comments, and accessibility issues.Politics, Religion & Geopolitics (00:20:42 - 00:41:55)Preference Deals & Jewish Community: Discussion on Labor's preference deals with the Greens in McNamara (open ticket for Josh Burns) vs. Isaacs (Mark Dreyfus), causing concern in the Jewish community. Mention of the Adas Israel synagogue firebombing and surrounding uncertainties/rumours.Pope Francis's Passing: Reflections on his papacy. Hong Kong Jack prefers John Paul II; Jack the Insider defends Francis and criticizes JP II over handling scandals. Discussion on potential successors and the slow pace of change in the Catholic Church.Easter & Religion: Easter memes, the role of the Catholic Church (charity vs. criticism), changes in Ireland, Catholics selectively following doctrine (e.g., contraception).India-Pakistan Tensions: Escalation following a militant attack in Kashmir. India threatens to cut off water supplies to Pakistan. Historical context, nuclear capabilities, and the danger of water rights disputes. Brief mentions of Pakistan's internal issues and conditions in Bangladesh.US Politics & Global Affairs (00:41:55 - 00:55:28)Trump & Trade: Trump walks back China tariff threats after meeting retail executives concerned about Christmas stock. Discussion on Trump's understanding of trade.US Courts & Executive Orders: Judge Kollar-Kotelly's ruling striking down parts of Trump's order requiring citizenship proof for voter registration, while upholding other sections. Discussion on the proper role of courts, checks and balances, and Congress's inaction leading to increased reliance on executive orders.Russia-Ukraine Peace Proposal: Details of a proposed deal involving US recognition of Russian control over Crimea/Eastern regions, no NATO for Ukraine, lifting sanctions vs. European security guarantees for Ukraine, return of some territory, etc. Criticism from Boris Johnson; seen as unfavourable to Ukraine. Trump's tweet urging Putin to stop strikes on Kyiv.Anniversaries & Culture (00:55:28 - 00:58:31)Saigon Evacuation: 50th anniversary of the Australian Embassy evacuation, noting local staff left behind.Crocodile Dundee: 39th anniversary. Paul Hogan's comments, investment success stories (Dennis Lillee).Yahoo Serious: Mention of a current court case.Sports: Cricket, AFL & More (00:58:31 - 01:29:28)Keith Stackpole (RIP): Tribute to the former Australian cricketer. Discussion of his career as a player (opener, aggressive batsman) and commentator. Anecdotes involving Bill Lawry, Kerry O'Keeffe, Harsha Bhogle.AFL Send-Off Rule Debate: Sparked by the Nash/Miers incident. Arguments for/against a red card, implementation challenges (timing, concussion protocols), historical examples, Lee Matthews' view.MCG Security & SCG Fan Ban: Increased security for ANZAC Day game. Discussion on the SCG Trust's two-year ban on a 16-year-old fan for throwing/dropping a record near Aliir Aliir – deemed excessive by the hosts.Noah Balta Controversy: Richmond player playing before being sentenced for assault. Criticism of Richmond's handling, the AFL's stance, player's curfew impacting availability, and political commentary surrounding the issue.Tom De Koning Contract: Rumoured huge offer from St Kilda. Discussion on his value, the Gawn/Grundy comparison, implications for both clubs, and the changing role/importance of elite ruckmen.NRL: Broncos defeat Bulldogs; several Bulldogs players facing bans. Roosters vs Dragons ANZAC match preview.Rugby & Cricket Updates: James O'Connor's late-game heroics; Cameron Green's century on County debut for Gloucestershire; IPL viewing challenges.Final Thoughts (01:29:28 - End)Meat Consumption Trends: Rebound in meat buying over plant-based alternatives.Unnecessary Technology: Comparison of plant-based foods and internet-connected fridges.ANZAC Day AFL Game: 30th anniversary of the Essendon vs Collingwood match, origins involving Kevin Sheedy and Gabby Allen.Wrap-up & Sign-off.

In this mega-episode, Stephen Donnelly goes on a whirlwind tour of Australia's most hotly-contested seats for Labor. He is joined by campaign experts (see below) from each state, who shine a spotlight on the candidates, the constituents, and the issues shaping each electorate.They share the betting odds and lay their predictions on the table. This is the ultimate election night primer.***Use the Chapter headings to jump to the seats that pique your interest - or listen to the whole episode like the absolute beast you are.***Can Labor get to 76 this Saturday night? Join us to find out. CHAPTERS:00:00 Introduction01:18 Welcome to NSW06:00 Bennelong12:42 Gilmore21:51 Paterson29:52 Hunter34:48 Robertson41:47 Welcome to QLD45:39 Leichardt54:39 Bonner01:03:23 Brisbane01:08:51 Longman01:14:16 Welcome to TAS01:15:44 Lyons 01:30:27 Bass01:35:49 Franklin01:38:22 Welcome to the NT01:39:20 Solomon01:48:18 Lingiari01:56:35 Welcome to SA02:00:42 Boothby02:10:19 Sturt02:19:41 Welcome to WA02:25:13 Bullwinkle02:29:32 Tangney02:37:16 Pearce02:42:47 Canning02:48:58 Welcome to VIC02:52:58 Chisolm 03:00:58 Menzies03:03:19 Aston03:07:50 Dunkley03:10:33 Bruce03:11:59 McEwan03:15:21 Hawke03:17:37 Mcnamara03:29:08 Wills 03:40:27 Wrap UpSPECIAL GUESTS:NSW - Todd PinkertonTodd is the director of campaigns and strategy at Unions NSW, a former federal and state Labor staffer, and he's been on every campaign cycle since 2011.QLD - Evan MoorheadEvan is the director of Anacta Strategies, former Director of Strategy for the Office of the Premier and Minister for Trade, former State Secretary for Queensland Labor, and former State Member for Waterford.WA - Priya BrownPriya is a partner at GRA Partners, the former Chief of Staff in the WA Government, a former Senior Advisor in the Vic Government, and the former Regional Field Director for the Community Action Network.TAS - Jack MilroyJack is a senior strategist and public affairs professional with more than 20 years of experience in progressive political campaigns in Australia and abroad.SA - Matt ClemowMatt is a former Senior Advisor and Chief of Staff in the SA Labor Government, to successive SA Labor Premiers and current consultant for Capetal Advisory in Adelaide.NT - Ryan NeveRyan has over 20 years of experience as an advisor in the NT Government, as well as stints in the UK and Victoria. Most recently he was Executive Director for the Finance, Communications, Policy, and Strategy Divisions within the Dept. of Environment, Parks, and Water Security in the NT. VIC - Jessie McCroneJessie is a managing partner at FMRS advisory, the former Deputy Chief of Staff to Daniel Andrews, and former ALP National Organiser.The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and Support the showNew episodes out every Friday.If you like the show leave a comment below or leave us a review on Podchaser: https://bit.ly/36uFbp8Support the show on Patreon. Follow us on YouTube, Facebook, X, Bluesky, and Instagram.

Early voting is now open, and E-Day is drawing near!Stephen Donnelly, Jessie McCrone, and David Feeney are back to unpack the previous week. Both campaigns briefly paused for Easter and out of respect for the passing of Pope Francis. Who was helped, and who was hurt by this hiatus? The hosts are joined by former digital strategist for Daniel Andrews and Jacinda Ardern, Reed Fleming.  Reed reveals what both major parties (and a few minor ones) have spent on their social media campaigns - plus their messaging missteps and sometimes bizarre attempts to go viral.Everyone wonders what the LNP campaign would look like if Dutton could be to his inner Darth Vader. Plus - your listener nominations!Mentioned in the episode:Reed Fleming's Good to Go https://www.goodtogo.digital/The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the showNew episodes out every Friday.If you like the show leave a comment below or leave us a review on Podchaser: https://bit.ly/36uFbp8Support the show on Patreon. Follow us on YouTube, Facebook, X, Bluesky, and Instagram.

Chooks, the election is just over a week away, and early voting is open, so we're talking about some tools you can use to make sure your vote is representing you and your values! Plus, we're reacting to some primo, pizzazz-less LNP vids. LINKS Visit the Vote Compass website https://bit.ly/4lGnto1 Visit the Build A Ballot website https://www.buildaballot.org.au/ Check out @itsalotpod on IG at https://bit.ly/itsalot-instagram Review the podcast on Apple Podcasts https://bit.ly/ial-review Follow LiSTNR Entertainment on IG @listnrentertainment Follow LiSTNR Entertainment on TikTok @listnrentertainment CREDITS Host: Abbie Chatfield @abbiechatfield Executive Producer: Lem Zakharia @lemzakhariaDigital and Social Producer: Oscar Gordon @oscargordon Recording Engineer & Editor: Amy Kimball @amy.kimballSocial and Video Producer: Zoe Panaretos @zoepanaretosIt's A Lot Social Media Manager: Julia ToomeyManaging Producer: Sam Cavanagh Find more great podcasts like this at www.listnr.com/See omnystudio.com/listener for privacy information.

This Week:Labor and the Liberals officially launch their campaigns.Peter Dutton's son Harry speaks for the average worker.Shadow Minister for Education Sarah Henderson wants to gut Free TAFE.And Jacinta Nampijinpa Price wants to Make Australia Great Again, but not like that. Obviously. Stephen Donnely, Jessie McCrone, and David Feeney have a lot to cover this week. They are joined by Victorian State Correspondent for Guardian Australia, Benita Kolovos, who gives a journo's-eye-view of life on the campaign trail. Plus your listener nominations!Mentioned in the episode:Socially Democratic's Solidarity Online Phone Banking Registration: https://thisislabor.org/get-involved/attend-an-event/socially-democratic-online-phone-bank/The presenting sponsor of the Socially Democratic podcast is Dunn Street. For more information on how Dunn Street can help you organise to build winning campaigns in your community, business or organisation, and make the world a better place, look us up at: dunnstreet.com.au Support the showNew episodes out every Friday.If you like the show leave a comment below or leave us a review on Podchaser: https://bit.ly/36uFbp8Support the show on Patreon. Follow us on YouTube, Facebook, X, Bluesky, and Instagram.

Amazed though I am, it appears the LNP has one policy which is so critical it should win the election. I am talking about Gas reverse tariffs. Recall that while East Coast Australia has doubled its gas production over the past decade, the domestic market has been supplied with 25% less gas. This has driven … Continue reading "Gas: One Policy To Rule Them All!…"

On May 3rd, just five weeks from now, Australians will be heading to the polls. The campaigning is underway after a visit to the Governor General by the Prime Minister. So, who will convince Australians they deserve to lead the country for the next three years, Anthony Albanese or Peter Dutton? It's an election with key policy differences so far all about the cost of living and energy policy.  Today, election analyst Casey Briggs explains why there's a growing number of swing voters.He's been looking at what they're thinking as politicians begin the hard sell.  We want you to help shape ABC News Daily's coverage of this election campaign. Send us a short voice memo telling us what's caught your attention in this campaign. We'll dedicate one episode each week of the campaign to explain a policy area and the politics around it with an expert or a journalist. We need topics and policies that a lot of people will be interested in. Email us: abcnewsdaily@abc.net.auFeatured: Casey Briggs, ABC election analyst

LNP is back. Tonight, J talks about the recently vandalized Newcomb's Ranch and how the ACH community was there to step in and help clean up. What's next for NR & GVBC? J takes your questions.Assistant Director of the Los Angeles Sheriff's Department, and friend to The Ryan's, MIKE LEUM is here to tell us all what it's like r3ponding to calls on Angeles Crest Highway, and all over the world. His task force responds internationally. How has the ACH community changed over the years? Is it better since GVBC? Worse?Viewer Mail: boxes have arrived from Chilao to New Jersey and there's no more room under J's desk… we have some unboxing to do.Plus Producer Arielle &new LNP merchandise and life gets real again his week! Thank you for being with us. Love one another. Live it while ya got it.#latenightplayset

Australians are guaranteed to head to the polls in the first five months of 2025.And while high interest rates and cost of living pressures are expected to be the top concerns for both major parties and voters, the battleground itself will also look different, with new changes to electoral seats and boundaries. Today, the ABC's Chief Elections Analyst Antony Green speaks with ABC News Radio's Tom Melville about why the next parliament is set to change.Featured: Antony Green, ABC Chief Elections Analyst